US Pharma MarketingThe post Ascletis receives FDA clearance to begin Phase III ASC30 programme appeared first on Clinical Trials Arena.
Ascletis receives FDA clearance to begin Phase III ASC30 programme
Ascletis Pharma has begun a global Phase III clinical programme for its once-daily oral small molecule GLP-1 receptor agonist, ASC30, for chronic weight management, following clearance from the US FDA. The post Ascletis receives FDA clearance to begin Phase III ASC30 programme appeared first on Clinical Trials Arena .
Ascletis Pharma has begun a global Phase III clinical programme for its once-daily oral small molecule GLP-1 receptor agonist, ASC30, for chronic weight management, following clearance from the US FDA.
Source: Clinical Trials Arena